Vivek Ramaswamy Quotes

Fundamental discoveries can and should be made in industry or academies, but to carry that knowledge forward and to develop a new drug to the market has to depend on the resources of industry.

When a company is fairly certain of a profit margin that is substantial, it can assume responsibility for the clinical trials to develop a blockbuster drug.

Financial risk is always associated with drug discovery. But the benefit that a blockbuster drug can bring to the business can be phenomenal if you can take that risk.

If you're trying to develop a new drug, that costs you a billion dollars to get through the FDA. If you want to start a software company, you can get started with maybe $100,000.

Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India.

And there are lots of drug companies that are working on cure or medicine.

One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.

No pharmaceutical company is making money by selling biological knowledge - they make money by selling chemicals. So getting as much of that knowledge as possible into the efficiency of the Web-commerce world is going to make it faster to find those chemicals.

We have 28,000 drug patents held by American universities that are not being developed.

If we can actually decrease the failure rate from nine out of 10 drugs failing in clinical trials and instead have seven out of 10 instead failing, that is a major victory for drug discovery and for people having better therapy.

I fell in love with the science at Merck.

It seems paradoxical that, as medical scientists make huge advances in discovering the mechanisms of common diseases, fewer and fewer innovative drugs are reaching the market.

I've heard drug experts say they believe if penicillin were discovered today, the FDA wouldn't license it.

It's a challenge between me and the hurdle, and the hurdle has always won.

Champions all get kicked when they're down.

I used to be a health-care investor a long time ago in the public markets. One thing I learned that we tried to apply here is that investing in small molecules, trying to invest in the next treatment, there's an element of gambling to that.

The United States has an active pharmaceutical industry that has brought huge benefits to the U.S. public. Most Americans, who benefit from these advances, have little understanding of how difficult it is to create an important new medical therapy and make it available to improve public health.

Any time you think you have the game conquered, the game will turn around and punch you right in the nose.

Even then, Vanderbilt was the premiere place for clinical pharmacology.

It’s our tax dollars that fund the initial research for these molecules that get transferred to corporations. We have an investment here… We end up paying for our drugs twice. We pay for the initial development through our tax dollars. And then when it goes on the market we pay their inflated prices.

With any success, there will always be a little bit of a negative.

A vigorous and profitable drug industry is not a problem to be solved but a goal to be encouraged.

To ensure that America remains the leader in medical innovation, we must reduce the costs of developing life-saving drugs and ensure that there are appropriate economic incentives in place to produce them.

It's hard to deal with defeat.

There is probably a promising drug candidate that has already been discovered for the treatment of Down syndrome that is sitting on the shelf of some drug company.